

NON-RENOUNCEABLE ENTITLEMENT OFFER – AMENDED TIMETABLE

Melbourne, Australia – 16 March 2026: Percheron Therapeutics Limited (**ASX:PER**) refers to its announcement date 16 March 2026 to undertake a Non-renounceable Entitlements Offer to raise up to approximately \$2.2 million.

The Company provides an updated timetable for the Entitlement Offer below noting the changes to the Ex Date and Record Date:

| Event | Date (2026)* |
|---|--|
| Lodgement of this Prospectus with ASIC | Monday, 16 March |
| Lodgement of Appendix 3B and Prospectus with ASX Announcement of Offers | Monday, 16 March |
| Ex Date | Thursday, 19 March |
| Record Date for the Entitlement Offer (Record Date) | 7.00pm (AEDT) on Friday, 20 March |
| Prospectus and Entitlement and Acceptance Form dispatched to Eligible Shareholders and the Company announces that this has occurred Opening Date of Offers | Tuesday, 24 March |
| Last day to extend the Closing Date of the Offers | Wednesday, 1 April |
| Closing Date of Offers | 5:00pm (AEST) on Wednesday, 8 April |
| Unless otherwise determined by ASX, New Shares quoted on a deferred settlement basis from market open | Thursday, 9 April |
| Announcement of the results of the Offers Allotment of New Shares and New Options and lodgement of Appendix 2A and Appendix 3G | Wednesday, 15 April |
| Anticipated date of quotation of New Shares issued under the Offers | Thursday, 16 April |

*The timetable is indicative only and subject to change. The Company retains the discretion, subject to the ASX Listing Rules and the Corporations Act, to alter any or all of these key dates at its discretion (generally or in particular cases), without prior notice.

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com.

This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors;
